Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • A Study of Anifrolumab for Patients with Cutaneous Lupus Erythematosus to Measure Changes in Skin and Blood Inflammation and Clinical Outcomes

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria
  • Study of VENT-03 tablets in adults with active cutaneous lupus erythematosus with or without systemic lupus erythematosus

    Recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Czechia France Hungary Poland Spain
  • Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

    Recruiting

    3 1 1
    Investigated Drugs:
    Belgium Bulgaria France Germany Hungary Italy +5
  • A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

    Not yet recruiting

    3 1
    Investigated Diseases:
    Belgium Bulgaria Czechia France Germany Greece +4
  • Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

    Not yet recruiting

    3 1
    Belgium Bulgaria France Germany Greece Italy +4
  • Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion

    Not recruiting

    2 1 1
    Investigated Drugs:
    Bulgaria Greece Poland Romania Spain
  • Study on IMVT-1402 for Patients with Active Cutaneous Lupus Erythematosus

    Not recruiting

    2 1
    Investigated Drugs:
    Bulgaria Germany Greece Poland Spain
  • Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

    Not recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Bulgaria Denmark France Germany Greece +7
  • Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

    Not recruiting

    4 1
    Investigated Drugs:
    Belgium Bulgaria France Germany Hungary Italy +5